Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study
Avtorji:Hochmair, Maximilian J (Avtor)
Morabito, Alessandro (Avtor)
Hao, Desiree (Avtor)
Yang, Cheng-Ta (Avtor)
Soo, Ross A (Avtor)
Yang, James C-H (Avtor)
Gucalp, Rasim (Avtor)
Halmos, Balazs (Avtor)
Wang, Lara (Avtor)
Golembesky, Amanda (Avtor)
Märten, Angela (Avtor)
Čufer, Tanja (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.
Ključne besede:lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study
Leto izida:2018
Založnik:Future Medicine Ltd
Izvor:Velika Britanija
UDK:616-006
ISSN pri članku:1744-8301
OceCobissID:521824025 Povezava se odpre v novem oknu
COBISS_ID:2048432753 Povezava se odpre v novem oknu
DOI:10.2217/fon-2018-0711 Povezava se odpre v novem oknu
Opombe:Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer; Nasl. z nasl. zaslona; Opis vira z dne 9. 1. 2019;
Število ogledov:691
Število prenosov:374
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (2,39 MB)
URL URL - Izvorni URL, za dostop obiščite https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
 
Nadgradivo:Future oncology
Future Medicine
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:2018 Maximilian Hochmair
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:19.10.2018

Nazaj